Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Rona Yaeger, MD
Advertisement
Articles by Rona Yaeger, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC
2
This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data
3
PEF Ablation Yields Local Control, May Elicit Immune Response in Solid Tumors
4
Identifying Common Toxicities with Targeted Therapies in GI Malignancies
5
